Dr. Rafael Rosell is Chief Medical Officer and President of the Dr Rosell Oncology Institute (Quirón Dexeus University Hospital, Hospital Quirón Teknon, Sagrat Cor University Hospital, Barcelona, and General de Catalunya Hospital, Sant Cugat dels Vallès, all part of the Quirónsalud Group). He is also Director of the Cancer Biology and Precision Medicine Program at the Catalan Institute of Oncology, Hospital Germans Trias i Pujol (Badalona, Barcelona, Spain), Chief Scientific Officer, Chairman & Founder of Pangaea Oncology SA (Barcelona), and Founder and President of the Molecular Oncology Research Foundation (Barcelona). He is also Founder and Director of International Relations and Projects, Spanish Lung Cancer Group (SLCG) and served as President of the same from 1991-2014. He is a member of the Foundation Council and Steering Committee of the European Thoracic Oncology Platform (ETOP).
Dr. Rosell’s contributions to translational medical oncology, with particular emphasis on the field of non-small-cell lung cancer with EGFR mutations, have earned him international recognition. He was the first to demonstrate a benefit in terms of progression-free survival in non-small-cell lung cancer patients with EGFR mutations treated with Tarceva® in the EURTAC trial.